Massoud Mahmoudi, DO
Internal Medicine · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Offices
- 2
Offices
2 locations · University of California San Francisco · 1,780 clinicians in this group
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Mahmoudi’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 74.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$2,192
Medicare paid this office $2,192 for 31 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 22 | $1,142 | $52 |
Who their Medicare patients are
31 Original Medicare patients in 2024. Average age 73 · Also on Medicaid 48% · Health risk score 1.62. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75%.
The office billed $14,550, Medicare allowed $3,115 and paid $2,192; for 37 services of 5 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 31 | 37 | 73 | 1.62 | $14,550 | $2,192 |
| 2023 | 29 | 77 | 75 | 1.18 | $16,022 | $4,203 |
| 2022 | 48 | 249 | 73 | 1.18 | $30,305 | $9,573 |
| 2021 | 16 | 193 | 74 | 0.78 | $9,133 | $4,969 |
| 2020 | 20 | 536 | 74 | 0.87 | $16,553 | $7,178 |
| 2019 | 51 | 356 | 74 | 1.35 | $28,349 | $8,015 |
| 2018 | 48 | 245 | 72 | 1.39 | $27,607 | $9,423 |
| 2017 | 53 | 107 | 73 | 1.47 | $24,640 | $6,500 |
| 2016 | 45 | 121 | 71 | 1.42 | $19,109 | $5,217 |
| 2015 | 44 | 228 | 73 | 1.14 | $19,163 | $5,245 |
| 2014 | 49 | 736 | 72 | 1.00 | $29,317 | $12,557 |
| 2013 | 74 | 475 | 70 | 1.10 | $35,752 | $13,368 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 17 | $2,143 | $82 |
| Short return visit (20+ min) | 12 | $909 | $61 |
2022: 2 services
| Return visit (30+ min) | 24 | $3,327 | $98 |
| Short return visit (20+ min) | 14 | $1,449 | $69 |
2020: 1 service
| Return visit (30+ min) | 11 | $1,580 | $83 |
2019: 1 service
| Return visit (30+ min) | 35 | $3,440 | $75 |
2018: 2 services
| Return visit (30+ min) | 26 | $4,119 | $88 |
| Short return visit (20+ min) | 12 | $656 | $47 |
2017: 3 services
| Return visit (30+ min) | 31 | $2,982 | $75 |
| Long return visit (40+ min) | 13 | $1,919 | $120 |
| Short return visit (20+ min) | 15 | $656 | $44 |
2016: 2 services
| Return visit (30+ min) | 17 | $2,407 | $75 |
| Short return visit (20+ min) | 24 | $1,397 | $47 |
2015: 1 service
| Short return visit (20+ min) | 19 | $732 | $39 |
2014: 2 services
| Return visit (30+ min) | 16 | $2,858 | $87 |
| Short return visit (20+ min) | 16 | $640 | $40 |
2013: 3 services
| Return visit (30+ min) | 15 | $3,746 | $87 |
| Long return visit (40+ min) | 13 | $1,712 | $95 |
| Short return visit (20+ min) | 35 | $1,456 | $38 |
Drugs they prescribed that Part D paid
$27,278
Pharmacies billed $27,278 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 183) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
137 generic and fewer than 11 brand-name prescriptions · $27,278 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Levothyroxine | 20 | $584 | $29 |
| Albuterol Sulfate Hfa | 16 | $466 | $29 |
| Lisinopril | 13 | $108 | $8 |
Year by year
| 2024 | 183 | 33 | 0% (0) | None | $27,278 |
| 2023 | 198 | 20 | 0% (0) | None | $30,542 |
| 2022 | 206 | 17 | 0% (0) | 27% | $20,922 |
| 2021 | 145 | 14 | 0% (0) | 26% | $21,094 |
| 2020 | 185 | 22 | 0% (0) | 27% | $24,253 |
| 2019 | 170 | 31 | 0% (0) | 38% | $22,757 |
| 2018 | 230 | 29 | None | 36% | $24,343 |
| 2017 | 365 | 41 | None | None | $24,884 |
| 2016 | 241 | 29 | 0% (0) | None | $11,917 |
| 2015 | 275 | 30 | None | 21% | $11,688 |
| 2014 | 288 | 28 | None | None | $17,190 |
| 2013 | 359 | 38 | None | None | $27,051 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Trelegy Ellipta | 11 | $7,485 | $680 |
| Linzess | 11 | $7,237 | $658 |
| Fluticasone-Salmeterol | 14 | $3,724 | $266 |
| Albuterol Sulfate Hfa | 17 | $870 | $51 |
| Levothyroxine | 19 | $426 | $22 |
| Atorvastatin | 14 | $156 | $11 |
| Azithromycin | 11 | $70 | $6 |
2022: 7 drugs
| Linzess | 12 | $6,363 | $530 |
| Fluticasone-Salmeterol | 12 | $2,266 | $189 |
| Albuterol Sulfate Hfa | 17 | $653 | $38 |
| Levothyroxine | 14 | $298 | $21 |
| Atorvastatin | 13 | $150 | $12 |
| Lisinopril | 13 | $62 | $5 |
| Azithromycin | 11 | $44 | $4 |
2021: 4 drugs
| Linzess | 12 | $6,419 | $535 |
| Levothyroxine | 17 | $501 | $29 |
| Atorvastatin | 17 | $338 | $20 |
| Amlodipine Besylate | 12 | $154 | $13 |
2020: 4 drugs
| Linzess | 11 | $5,069 | $461 |
| Levothyroxine | 19 | $474 | $25 |
| Atorvastatin | 20 | $417 | $21 |
| Amlodipine Besylate | 25 | $185 | $7 |
2019: 3 drugs
| Levothyroxine | 24 | $605 | $25 |
| Atorvastatin | 17 | $484 | $28 |
| Amlodipine Besylate | 14 | $200 | $14 |
2018: 5 drugs
| Linzess | 12 | $4,713 | $393 |
| Levothyroxine | 25 | $618 | $25 |
| Atorvastatin | 24 | $577 | $24 |
| Diazepam | 12 | $121 | $10 |
| Amlodipine Besylate | 17 | $80 | $5 |
2017: 10 drugs
| Januvia | 11 | $9,531 | $866 |
| Eliquis | 12 | $4,711 | $393 |
| Atorvastatin | 41 | $739 | $18 |
| Ventolin Hfa | 13 | $698 | $54 |
| Venlafaxine Hcl Er | 11 | $501 | $46 |
| Levothyroxine | 13 | $360 | $28 |
| Gabapentin | 15 | $289 | $19 |
| Amlodipine Besylate | 34 | $203 | $6 |
| Lisinopril | 21 | $83 | $4 |
| Diazepam | 13 | $80 | $6 |
2016: 10 drugs
| Advair Diskus | 12 | $4,097 | $341 |
| Atorvastatin | 17 | $354 | $21 |
| Levothyroxine | 11 | $250 | $23 |
| Gabapentin | 11 | $225 | $20 |
| Lisinopril | 24 | $175 | $7 |
| Valsartan | 11 | $134 | $12 |
| Omeprazole | 16 | $129 | $8 |
| Amlodipine Besylate | 16 | $127 | $8 |
| Lorazepam | 12 | $41 | $3 |
| Hydrochlorothiazide | 18 | $33 | $2 |
2015: 6 drugs
| Amlodipine Besylate | 36 | $285 | $8 |
| Lisinopril | 33 | $262 | $8 |
| Levothyroxine | 12 | $226 | $19 |
| Lorazepam | 14 | $195 | $14 |
| Omeprazole | 13 | $132 | $10 |
| Hydrochlorothiazide | 19 | $68 | $4 |
2014: 9 drugs
| Advair Diskus | 18 | $5,181 | $288 |
| Amlodipine Besylate | 44 | $301 | $7 |
| Montelukast | 15 | $285 | $19 |
| Doxepin | 12 | $180 | $15 |
| Atorvastatin | 15 | $149 | $10 |
| Lisinopril | 23 | $99 | $4 |
| Finasteride | 11 | $78 | $7 |
| Sertraline | 11 | $56 | $5 |
| Hydrochlorothiazide | 17 | $50 | $3 |
2013: 10 drugs
| Advair Diskus | 25 | $6,839 | $274 |
| Montelukast | 21 | $644 | $31 |
| Amlodipine Besylate | 37 | $496 | $13 |
| Atorvastatin | 12 | $264 | $22 |
| Doxazosin Mesylate | 16 | $171 | $11 |
| Doxepin | 12 | $143 | $12 |
| Lorazepam | 22 | $139 | $6 |
| Lisinopril | 16 | $134 | $8 |
| Finasteride | 12 | $98 | $8 |
| Sertraline | 11 | $59 | $5 |
Money from drug and device companies
$493 in 2025
| 2025 | 1 | 4 | None | $493 |
| 2024 | 1 | 1 | None | $47 |
| 2020 | 1 | 1 | None | $27 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| GlaxoSmithKline | Nucala | $493 | 4 payments
|
See all 4 published payments
| GlaxoSmithKline | Meals · 2025-11-19 | None | $125 |
| GlaxoSmithKline | Meals · 2025-08-20 | Nucala | $122 |
| GlaxoSmithKline | Meals · 2025-06-25 | Nucala | $125 |
| GlaxoSmithKline | Meals · 2025-03-13 | Nucala | $121 |
See earlier years (2024, 2020)
2024: $47
| Blueprint Medicines | Ayvakit | $47 | 1 payment
|
2020: $27
| Aimmune Therapeutics | Palforzia | $27 | 1 payment
|
Professional record
- NPI
- 1255402640
- Licence
- CA 20A7157
- Trained
- At Still University of Health Sciences, College of Osteo Med, Kirksville, 1994
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Medicaid ID
- CA 0020A71570
- Taxonomy
- Federal specialty code 207K00000X (207K00000X); Internal medicine (207R00000X)
- Mailing address
- 812 Pollard Rd, Suite 5, Los Gatos, CA, 95032
- NPI first listed
- 2006-11-10
- NPI last updated
- 2010-01-19
This is when the NPI record was last certified, not a medical board exam.